Newcells: Our Company - Newcells

Retinal platform

An in vitro, light responsive, retinal model for accurate predictions of in vivo outcomes you can have confidence in.


Kidney platform

The most advanced near-physiological high throughput kidney proximal tubule cells (PTC) model to investigate drug transport modalities in vitro.

Lung epithelia model

Lung model

A model to investigate airway physiology, viral infection, drug safety and environmental impacts on lung airway epithelia.

Sinusoid iPSC-derived Liver model

Liver model

We are developing a model of liver sinusoid derived from human induced pluripotent stem cells (iPSC).

Newcells: Our Company

Newcells mission is to de-risk the decision-making process in drug development by providing best in class in vitro models that most accurately predict in vivo outcomes.

Based in Newcastle upon Tyne, UK

Founded in 2015 with academics from Newcastle University

Strong links with global Pharmaceutical and Biotech companies and academic centres of excellence

State of the art facilities located in The Helix science campus

Fast growing company – growing to 100 employees by 2025

£10M raised since its inception, £7M equity and £3M non-dilutive

Newcells builds functionally relevant in vitro models that accurately predict in vivo outcomes. Globally recognised scientific expertise and innovation is embedded in all it’s products and services.

Using our expertise in induced pluripotent stem cells (iPSCs), cellular physiology and organoid technology, we engineer models of kidney, retina, liver and lung from patient samples as well as from a range of preclinical species.

State-of-the-art 2D and 3D cell-based assays

Newcells is a fast-growing team of global scientific and industry experts located in The Biosphere, Newcastle upon Tyne and our purpose is to bridge the gap between scientific discovery and patients. We make a difference by providing better predictions of clinical outcomes. Using our expertise in induced pluripotent stem cells (iPSCs), cellular physiology and organoid technology, we build functional pre-clinical in vitro models of kidney, retina, liver and lung.

Newcells offering for drug development

Powerful assays to support critical decision-making during drug development.



Best in class in vitro models for accurate predictions of in vivo outcomes 

  • Most physiologically relevant in vitro models  
  • More predictive models for better in vivo outcomes, outperforming other existing in vitro models 
  • Recapitulates the complexity and architecture of human tissues 
  • Enables cross-species comparative studies 
  • Ideal for human diseases where no other models are available (e.g., retina) 
  • More suited to High Throughput screening than other models currently available 
  • More cost effective than other models currently available
Newcells Biotech

Model Applications

  • Disease modelling 
  • Gene therapy applications 
  • Respiratory infectious diseases 
  • Vaccine development 
  • Gene editing applications 
  • Translational science (mechanistic insights) 
  • Safety and efficacy studies 
  • DMPK and toxicology studies 
  • Transporter studies 
  • Drug-drug interactions (DDI) studies 
  • Xenobiotic metabolism of chemicals 
  • Drug mechanism of action 

Our Investors

Newcells is funded by the founders, venture and private equity investors

State-of-the-art 2D and 3D cell-based assays